FDA Opens Door for Single-Phase 3 Trial Pathway for Acurx’s Ibezapolstat — Acurx Pharmaceuticals, Inc.

Event summary

FDA indicated openness to a single-Phase 3 trial pathway for ibezapolstat’s NDA submission, contingent on robust efficacy data.
IBZ-ASPIRE Phase 3 trial design agreed upon, targeting both acute treatment and recurrence reduction of C. difficile infection (CDI).
IBZ-PATHFINDER open-label pilot trial in recurrent CDI patients set to begin enrollment in Q4 2026.
Acurx holds FDA QIDP and Fast-Track designations for ibezapolstat, with EMA SME designation.

The big picture

The FDA’s guidance reflects a strategic shift toward streamlining antibiotic approvals for urgent unmet needs, particularly in recurrent infections. With C. difficile responsible for ~500,000 U.S. infections annually and recurrence rates up to 40%, ibezapolstat’s potential to address both acute treatment and prevention could reshape the $5B CDI market. Acurx’s ability to leverage its QIDP/Fast-Track status will be critical in accelerating time-to-market.

What we're watching

Regulatory Flexibility: Whether FDA’s case-by-case approach to single-trial NDAs will set a precedent for other antibiotic developers.
Clinical Execution: The pace at which Acurx can secure funding and initiate the international IBZ-ASPIRE Phase 3 trial.
Market Differentiation: How ibezapolstat’s microbiome-sparing profile will position it against existing CDI treatments like vancomycin and fidaxomicin.